ISBN 9783843907606

978-3-8439-0760-6, Reihe Tiermedizin

Lisa Zimmermann
Evaluation der Wirksamkeit und Sicherheit einer Mycoplasma hyopneumoniae Vakzine bei Ferkeln in der ersten Lebenswoche

72 Seiten, Dissertation Ludwig-Maximilians-Universität München (2012), Softcover, A5

Zusammenfassung / Abstract

Aim of this study was to evaluate the safety and efficacy of Suvaxyn® MH-One (Pfizer GmbH, Berlin, Deutschland), an inactivated M. hyopneumoniae-vaccine administered to piglets aged one week under field conditions. For this reason a farrow to finish farm in southern Germany with evidence of M. hyopneumoniae in PCR and ELISA and accordant clinical findings without a recent M. hyopneumoniae-vaccination was selected. 240 piglets aged 4 to 5 days were enrolled in the study according to a random treatment allocation plan and assigned to one vaccine group and one control group. Each piglet of the vaccine group received an injection with 2ml of the vaccine intramuscular in the neck. The control group received 2ml 0.9% saline the same way as the vaccine group. To evaluate the efficacy of the vaccine the bodyweight was monitored on study day 0, 28, 84, 140 and 168 and the average daily weight gain was calculated. Furthermore a lung score at abattoir as well as the development of the antibodies in the blood after the vaccination was measured. 25% of the vaccine group and 25% of the control group were assigned to a safety group based on a randomisation plan. Animals in the safety group obtained clinical observations and the injection site was observed regarding reactions before and after the injection. This procedure was performed on a daily basis for 14 days. A significant difference in bodyweight of 4kg (p=0.0034), 4.5kg respectively (p=0.0073) is measured at onset of the final fattening phase and on day 168, the last time bodyweight was taken. The average daily weight gain of both groups is 50g higher in the vaccine group between day 84 and day 140 (p=0.0039). During the hole trial period with 30g the average daily weight gain of the vaccine group is significantly higher (p=0.007). Between day 84 and 140 the development of the antibodies in the serum of the animals shows a significant difference in favour of the vaccine group (p=0.0072). At abattoir 9% of the lung in the control group shows lesions compared to 5% of the lung in the vaccine group (p=0.0001). The safety of the vaccine can be evaluated by clinical observations and injection site observations. No signs of abnormal health, no increase of average rectal temperature over physiological ranges and no injection site reactions are observed. It can be concluded, that the application of Suvaxyn® MH-One on one week old piglets can be stated as save and efficient.